Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
Recent posts
-
Six patients with the rare genetic disorder Fabry disease have filed a lawsuit against Cambridge, MA-based biotech company Genzyme (NASDAQ:GENZ) and Mt. Sinai Medical School over the handling of... Read more »
-
Cambridge, MA-based Epizyme has nabbed another pharmaceutical partnership. Two months after announcing a deal worth as much as $650 million with GlaxoSmithKline (NYSE:GSK), the startup says today that it... Read more »
-
Here’s a startup that is stepping out of top-secret status in style. Microsoft Chairman Bill Gates, the second-most wealthy person in the world, is one of two new seed investors in... Read more »
-
Stonewedge, an Andover, MA-based startup focused on improving care for seniors, has raised $1 million in an equity financing, according to an SEC filing. The company provides scant details about... Read more »
-
Genzyme chief executive Henri Termeer is due to take in $158.4 million from French drug giant Sanofi-Aventis’s buyout of his Cambridge, MA-based biotech firm, Bloomberg reported. Termeer is also eligible... Read more »
-
Lexington, MA-based Imprivata is among the software companies that is benefiting from the push in the U.S. and abroad to adopt electronic health records. And the venture-backed company seems to have... Read more »
-
Bessemer Venture Partners, which has offices in Cambridge, MA, and Menlo Park, CA, wants to raise as much as $1.5 billion for a fund to invest in technology startups, two unnamed... Read more »
-
Three companies involved in the development of a once-weekly injection of the Type 2 diabetes drug exenatide reported today that the treatment did not provide superior efficacy over an existing treatment... Read more »
-
Speculation raged for months about the potential impacts of a Sanofi-Aventis (NYSE: SNY) takeover of Genzyme (NASDAQ: GENZ). Yet now that the French drug giant and Cambridge, MA-based biotech... Read more »
-
One of Biogen Idec’s rivals in the development of oral multiple sclerosis drugs got some bad news from the FDA. The agency has informed Germany-based Merck KGaA that it wants more... Read more »
-
Cardiorobotics, a developer of a robotic catheter for heart procedures, has raised $6.6 million of a planned $12.5 million round of equity and rights financing, according to an SEC filing.... Read more »
-
RXi Pharmaceuticals (NASDAQ:RXII), a Worcester, MA-based biotech focused on RNA interference treatments, has priced a public offering of common stock and warrants expected to gross $8.1 million, according to... Read more »
-
Agrivida scientists plan to be at an event this week supported by the U.S. Department of Energy in the Washington, DC, area, where the startup will show industry leaders its way... Read more »
-
[Updated---03/01/11, 8:30 am ET] Investors have been getting behind a Marlborough, MA-based firm that is working on a potentially better way to treat an irregular heart rhythm known as atrial fibrillation.... Read more »
-
The FDA has given a complete response letter to Israel-based Protalix Biotherapeutics for the company’s application for marketing approval of an protein therapy for Gaucher’s disease, the firm announced this morning.... Read more »
-
ImmunoGen, in the eyes of Wall Street, is largely defined by one thing—its relationship with industry giant Genentech. That’s because Genentech uses ImmunoGen’s technology to help amp up the antibody trastuzumab... Read more »
-
Waltham, MA-based Thermo Fisher Scientific (NYSE:TMO) says it has inked deals to sell its Athena Diagnostics and Lancaster Laboratories businesses for a total of $940 million in cash to... Read more »
-
Metamark Genetics has graduated from stealth mode. Now the Cambridge, MA-based startup, founded by top scientists at Harvard University and elsewhere, has hired a diagnostics industry veteran as its chief executive,... Read more »
-
Vertex Pharmaceuticals’ winning ways are being felt on Wall Street this morning. The Cambridge, MA-based drug developer’s (NASDAQ:VRTX) shock price was up 15 percent to $44:03 per share as... Read more »
-
Acetylon Pharmaceuticals, a developer of drugs that inhibit HDAC enzymes to treat cancer and autoimmune diseases, has raised $12.4 million of a proposed $30 million second round of equity financing, according... Read more »
Page 3 of 55 « previous page · next page »
